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Abstract
To clarify the importance of deleted protein and tRNA genes on the impairment of mitochondrial function, we performed a quantitative
analysis of biochemical, genetic and morphological findings in skeletal muscles of 16 patients with single deletions and 5 patients with
multiple deletions of mtDNA. Clinically, all patients showed chronic progressive external ophthalmoplegia (CPEO). The size of deletions
varied between 2.5 and 9 kb, and heteroplasmy between 31% and 94%. In patients with single deletions, the citrate synthase (CS) activity
was nearly doubled. Decreased ratios of pyruvate- and succinate-dependent respiration were detected in fibers of all patients in comparison to
controls. Inverse and linear correlations without thresholds were established between heteroplasmy and (i) CS referenced activities of the
complexes of respiratory chain, (ii) CS referenced maximal respiratory rates, (iii) and cytochrome-c-oxidase (COX) negative fibers. In
patients with single and multiple deletions, all respiratory chain complexes as well as the respiratory rates were decreased to a similar extent.
All changes detected in patients with single deletions were independent of deletion size. In one patient, only genes of ND5, ND4L as well as
tRNALeu(CUN), tRNASer(AGY), and tRNAHis were deleted. The pronounced decrease in COX activity in this patient points to the high
pathological impact of these missing tRNA genes. The activity of nuclear encoded SDH was also significantly decreased in patients, but to a
lesser extent. This is an indication of secondary disturbances of mitochondria at CPEO.
In conclusion, we have shown that different deletions cause mitochondrial impairments of the same phenotype correlating with
heteroplasmy. The missing threshold at the level of mitochondrial function seems to be characteristic for large-scale deletions were tRNA and
protein genes are deleted.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Since the first reports linking human diseases to genetic
defects of the mitochondrial genome, fast and exciting
progress in understanding of the pathophysiology of mito-
chondrial diseases has been possible [1]. However, in
mtDNA-linked diseases, strong relations between genotype
and phenotype are missing [2,62–64]. Chronic progressive
external ophthalmoplegia (CPEO), for instance, is caused by
single deletions of mtDNA occurring sporadically [3], by
autosomally inherited multiple deletions of mtDNA [4],
duplicated mtDNA [5], A3243G mutation [6,7], or by other
point mutations [8,9]. Autosomal inheritance is a hint at
mutations of the nuclear genome. Mutations in the AdN-
translocator [10], twinkle [11], and polymerase c genes [12]
have been identified.
Deletions of mtDNA have at least two different conse-
quences at different levels of mitochondrial protein synthesis.
Missing protein genes cause a defined enzyme deficiency due
to a defect at the level of transcription. The resulting impair-
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ment at the level of mitochondrial function depends on the
control exercised by the deleted protein on the function in
total. Missing tRNA, however, causes dysfunction due to a
defect at the level of translation. This translation defect
necessarily affects all mitochondrial encoded structure pro-
teins and should a priori have a higher impact on the impair-
ment of mitochondrial functioning than deletions of protein
coding genes.
It is not known for certain whether or not deletions of
mtDNA at different levels of heteroplasmy correlate with
altered patterns of mitochondrial enzymes [13,63] and how
these altered enzyme patterns influence functional properties
of mitochondria [14,15] Generally, it is assumed that only
pronounced enzyme defects are detectable, since the max-
imum activity of most single enzymes is higher than the
maximum fluxes through the metabolic systems [14,16].
This is the metabolic reason for thresholds. A threshold of
55% was detected in cybrids with common deletion [17],
and in resting fibroblasts, there was no detectable effect of
MELAS mutation on the rate of ATP synthesis [18]. In
contrast to these results, there are patients with mt-encepha-
lomyopathies due to mutations at low heteroplasmy but with
considerable clinical symptoms [7,63]. In addition, it has
been recently shown that linear changes in respiratory chain
complexes without threshold were detectable in muscle
biopsies of CPEO patients [13]. Due to these problems, a
complex set of approaches at the level of genome, enzymes,
and on the level of mitochondrial function is necessary to
clarify the genotype phenotype relations for the different
types of mutation.
Usually, mitochondrial function is investigated in iso-
lated mitochondria [19–22]. Due to the existence of differ-
ent mitochondrial subpopulations [23 – 26] and the
nonhomogeneous distribution of defective mitochondria
[25], it is uncertain whether or not mitochondrial prepara-
tions normally obtained with a low yield [19,20] can be
representative of the total amount of mitochondria. As an
alternative, the skinned fiber technique allows practically all
mitochondria contained in muscle fibers to be investigated
[27–29]. In combination with high-resolution respirometry
[30] and multiple substrate inhibitor titration [31], this
method has been introduced for the diagnosis of mitochon-
drial disorders [27,29,31,32]. These techniques have been
successfully used for detection and characterization of
mitochondrial defects in heart [33] and skeletal muscle
[31,33] and for estimation of flux control coefficients as
well [34].
The aim of our present study was to define quantitative
relations between mt-defects on genomic, enzymatic and
functional level of mitochondria in the skeletal muscle of
21 patients with single and multiple deletions. We included
in our study patients with deletions of different size in
order to compare their importance on the degree of
mitochondrial impairment. Functional properties of mito-
chondria in skinned fibers were compared with activities of
mitochondrial enzymes, the nature, size, and heteroplasmy
of the genetic defect. If functional and enzymatic proper-
ties were normalized by CS activity, both kinds of data
were found to correlate linearly with the level of hetero-
plasmy. Non-normalized data, however, did not correlate
with heteroplasmy but showed high thresholds. Results
support the view that the consequences of deletions on
enzymatic and functional level correlate with the hetero-
plasmy and not with the deletion size. Therefore, it is
concluded that patients with common and similar deletions
as occurring in our patients have comparable impairments
at mitochondrial level, which differ only in the level of
heteroplasmy.
2. Materials and methods
2.1. Patients
Twenty-one patients suffering from CPEO (mean
age=45F14 years; 10 male, 11 female) due to multiple
(n=5) or single deletions (n=16) were included in this
study. Clinical diagnosis was supported by a broad spec-
trum of specific investigations: characteristic histological
and ultrastructural changes, increased blood lactate levels
after mild bicycle exercise [35], increased muscle fatigue
[36], and monitoring of muscle oxygenation during exer-
cise by NIRS [36,37]. Control muscle specimens were
obtained from 46 patients (23 male and 23 female, mean
age 50F16 years) who had muscle biopsies for diagnosis
of muscular symptoms. Patients were deemed to be normal
controls if they were ultimately found to have no muscle
disease by combined clinical, electromyographic, and his-
tological criteria.
2.2. Biopsies
Open biopsies were taken from m. biceps brachii (14), m.
quadriceps (2), m. vastus lateralis (3), m. deltoideus (1) or
from m. pectoralis (1). Biopsies (about 300 mg) were divided
into three parts. Two parts were immediately frozen in liquid
nitrogen for enzymatic and histochemical investigations.
One part was stored on ice at 4 jC in high energy buffer
solution (high energy preservation solution (HEPS) [31],
consisting of 8.1 mM K-EGTA, 1.9 mM CaEGTA buffer
(free Ca2+ concentration 0.1 AM), 9.5 mM MgCl26H2O, 3
mM KH2PO4, 20 mM taurine, 5.2 mM ATP, 15 mM PCr, 49
mM KMES, 20 mM imidazole, pH 7.1) after rough dis-
section. It has been shown that mitochondrial function
remains intact up to 30 h under these conditions [28].
2.3. Molecular genetic investigations
DNA was extracted from muscle and digested with
BamHI or PvulI prior to Southern blotting and hybridization
to a mtDNA probe of 16252 nucleotides (Expand long PCR
system, Boehringer Mannheim, forward primer 15149–
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15174, reverse primer 14831–14811). DNA was labeled
with the ECL kit (Amersham Life Science), before an
autoradiogram was performed (Biomax-film, Kodak [7]).
The deletions were mapped using restriction analysis. The
proportions of mutated mtDNA were determined using
ImageQuant software (Molecular Dynamics) using the ‘area
of rectangle method’ according to the manufacturer’s
instructions after correction by the molecular weight. In
three patients with familial CPEO and multiple deletions,
the whole coding region of the ANT-1 gene was analyzed by
direct sequencing according to Kaukonen et al. [10].
2.4. Isolation and permeabilization of muscle fibers
Immediately before oxygraphic measurements, the fibers
were permeabilized for 30 min with 50 Ag saponin/ml of
HEPS as described previously [31]. After permeabilization,
the fibers were washed three times (10 min) in incubation
medium (see below) to remove saponin and adenine nucleo-
tides. All procedures were performed in a cooling room on
ice at 4 jC.
2.5. Respirometric measurements
We used the OROBOROSR oxygraph [30], a two-cham-
ber respirometer with a Peltier thermostat and integrated
electromagnetic stirrers. Bundles of fibers (5–10 mg) were
transferred into the oxygraph chambers. The measurements
were performed at 30 jC in 1.42-ml incubation medium
consisting of 75mMmannitol, 25mM sucrose, 100mMKCl,
10 mM KH2PO4, 0.5 mM EDTA, 5 mM MgCl2, 20 mM
Tris–HCl and 1 mg/ml BSA, (pH 7.4) using different sub-
strates: 10 mM pyruvate+2 mM malate and 10 mM succi-
nate+5 AM rotenone. The oxygen concentration in the air-
saturated mediumwas considered to be 200 nmol O2/ml at 95
kPa barometric pressure. The weight-specific oxygen con-
sumption was calculated as the time derivative of the oxygen
concentration (DATGRAPH Analysis software, OROBO-
ROSR). The rate of state 3 respiration was determined
following the addition of 5 mM ADP. State 4 respiration
was measured after the addition of 1.8 mM atractyloside.
2.6. Preparation of muscle homogenates
Small pieces of frozen tissue were homogenized (1/30
weight per volume) in a solution containing 50 mM TRIS
buffer (pH 7.5), 100 mM KCl, 5 mM MgCl2, and 1 mM
EDTA using a glass/glass homogenizer (Kontes Glass Co.
Vineland, NJ, 2 ml, 0.025 mm clearance) as described
previously [38].
2.7. Enzyme determinations
Enzymatic measurements were performed in muscle
homogenates. Enzyme activities were assayed at 30 jC
spectrophotometrically using a DU 640 photometer (Beck-
man Instruments, Palo Alto, USA). Assays were run in
duplicates with two different quantities of sample. Enzyme
activities were referenced to noncollagen protein (NCP) or to
the activity of mitochondrial marker enzyme citrate synthase
(CS) as measured in the same sample.
The activity of rotenone-sensitive NADH:CoQ1 oxi-
doreductase (complex I) was measured in 100 mM
phosphate buffer (pH 7.4) containing 1 mM KCN, 60
AM CoQ1 and 100 AM NADH at 340 nm according to
Estornell et al. [39].
NADH:cytochrome-c-oxidoreductase (complex I+III),
succinate:cytochrome-c-oxidoreductase (complex II+III),
and ubiquinone:cytochrome-c-oxidoreductase (complex III)
were measured following the reduction of cytochrome c at
550 nm using an e of 19.1 mM1 cm1. Activity of complex
I+III was determined as the antimycin A- and rotenone-
sensitive fraction of total NADH-cytochrome c oxidoreduc-
tase slightly modified according the method described by
Hatefi and Rieske [40] in the presence of antimycin A [41].
Complex II and complex II+III were measured as described
by King [42]. Complex III was measured as described by
Kra¨henbu¨hl et al [43]. Activity of cytochrome-c-oxidase
(COX) was estimated by oxidation of reduced beef heart
cytochrome c as described by Wharton and Tzagoloff [44].
The use of diluted homogenates allows linear enzyme rates to
be obtained. CS was determined as described by Shepert and
Garland [45].
2.8. Protein determination
NCP was determined by the BCA assay [46] after
digestion of the homogenate with sodium hydroxide (50
mM) and pelleting the insoluble collagen protein by cen-
trifugation (12,000g for 10 min) as described previously
[38]. BSA was used as a standard.
2.9. Histochemistry
Cryostat sections of muscle biopsies were carried out on
10-Am slices. Sequential demonstration of COX and SDH
activities was performed with an adapted protocol described
in Ref. [47]. COX activity was demonstrated by using a
medium containing 4 mM 3,3-diaminobenzidine tetrahydro-
chloride and 100 AM cytochrome c, 10 U/l catalase in 50 mM
phosphate buffer, pH 7.4 at 37 jC for 60 min. After rinsing in
50 mM phosphate buffer, SDH activity was stained by using
1.5 mM nitroblue tetrazolium, 0.2 mM phenazine methosul-
fate and 1 mM sodium azide in 50 mM phosphate buffer, pH
7.4 at 37 jC for 40min. All blue fibers were counted as COX-
negative fibers. Other stainings were done using standard
methods [48].
2.10. Statistics
The mean values and standard deviations are calculated
from the number (n) of subjects. Significance was tested
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with unpaired Students’ t-test. Correlation for all data
including controls were tested with Pearson’s test using
SigmaStat-software. In addition, the correlation was calcu-
lated for the patients’ data only.
3. Results
3.1. Molecular defects of mtDNA
Molecular genetic investigations revealed in 16 patients
single deletions with a length of 2.5–9 kb. The hetero-
plasmy varied between 31% and 94%. In five patients,
multiple deletions were detected with a heteroplasmy
between 26% and 63%. Three of these patients had an
autosomal inheritance. No mutations were detectable in the
AdN-translocator gene I of these patients.
To evaluate the biochemical consequences of differences
in the affected genes, three patients with large differences in
the size of deletion but with similar levels of heteroplasmy
were selected for exact determination of the localization of
the deletion. In Patient 1, with the largest deletion of 9 kb,
all genes between cytochrome b and ATPase 8 were deleted
(Table 1). In patient 3, with the smallest deletion, only ND5
and ND4L as well as tRNALeu(CUN), tRNASer(AGY) and
tRNAHis were affected. Patient 2 had the common deletion.
Biochemical consequences of these different deletions are
presented below. Table 1 contains the structure of deleted
genes of four additional patients. Two of them had the
common and two had smaller deletions. In all investigated
patients, the three tRNA for histidine, serine, and leucine
were missing.
3.2. Changes at the level of respiratory chain enzymes
As shown in Table 2, there was a significant increase in
CS in the biopsies of patients with both single and multiple
deletions from 63F18 U/g NCP (control) to 115F74 U/g
NCP (single) and 81F19 U/g NCP (multiple). Fig. 1 shows
that the specific CS activities of all patients positively
correlated with heteroplasmy of deletions. This correlation
was even significant for the data of the patients only (with-
out controls). However, there are patients with high levels of
heteroplasmy and normal CS activity. This large variation of
CS activity (range 52–352 U CS/g NCP) is a clear indica-
tion of the necessity to scale enzymatic and functional data
by activity of CS as marker for the content of mitochondria
(normalization). As shown in Fig. 1B, the deletion size did
not correlate with CS activity.
Normalized activities of respiratory chain enzymes for
patients with multiple and single deletion and the controls are
collected in Table 2. Normalized COX activity was signifi-
cantly reduced (44%) in both groups of patients. In Fig. 2A,
normalized COX activities were plotted versus heteroplasmy.
In both groups of patients, the normalized COX activity
significantly decreased with increasing heteroplasmy. In
Fig. 2B, the CS-referenced COX activity was plotted versus
the size of deletions. As in the case of CS activity, there was
obviously no correlation between these parameters, indicat-
ing that deletions, even with large differences in the size of
deletion, have similar effects on the COX activity.
Normalized activity of complex III (Table 2) was also
significantly diminished in patients with single (41%) and
multiple (29%) deletions. Complex III activity correlated
with theheteroplasmyof single andmultipledeletions.Similar
results were found for complex I+III (single deletions67%;
multiple deletions33%), and for complex I (single deletions
31%;multipledeletions27%).Onlythechanges inpatients
with single deletions were significant. The correlation with
heteroplasmy was significant for complex I+III but not for
complex I.
Succinate dehydrogenase is a nuclear coded mitochon-
drial protein and should not be influenced by deletions of
mtDNA. However, the normalized activity of succinate
dehydrogenase was decreased too (27% single deletions;
19% multiple deletions) even with a significant correla-
tion to heteroplasmy.
Furthermore, activity of complex II+III was decreased
(46% single deletions and 36% multiple deletion),
significantly correlating with heteroplasmy.
3.3. Detection of functional impairment of muscle
mitochondria
Multiple substrate inhibitor titration and high resolution
respirometry was applied to characterize the mitochondrial
function in skinned fibers of muscle biopsies. Three typical
oxygraphic traces (respirograms) are shown in Fig. 3. In the
presence of 10 mM pyruvate, 2 mM malate, and 5 mM ADP,
Table 1
Localization and heteroplasmy of deletions in skeletal muscle biopsies of
three index patients and four further CPEO patients
(*) common deletion.
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Table 2
Biochemical, genetic and morphological data as detected in muscle biopsies of patients with single and multiple deletions of mtDNA
Single Patient 1 Patient 2 Patient 3 Multiple Single and multiple Controls r Slope
CS [U/g NCP] 115F74z(n=15) 55 131m 109m 83F19z (n=5) 109F67z (n=20) 63F18 0.58 1.61
COX/CS [%] 58F24# (n=16) 51x 48x 54x 58F21#* (n=4) 56F20# (n=20) 104F25 0.75 0.93
III/CS [%] 92F39# (n=16) 89x 53x 82x 110F33#* (n=5) 94F37# (n=21) 156F48 0.69 0.81
II+III/CS [%] 14F9# (n=16) 12x 17.9x 24 18F5 (n=5) 15F8# (n=21) 28F8 0.67 0.80
SDH/CS [%] 36F12# (n=16) 32x 32.9x 43x 40F3 (n=5) 36F11# (n=21) 48F13 0.45 0.42
I+III/CS [%] 4F2# (n=16) 2x 3x 6x 8F3 (n=5) 5F3# (n=21) 12F6 0.59 1.07
I/CS [%] 12F6#* (n=11) n.d. 6.7x n.d. 12F7 (n=5) 12F6#* (n=16) 17F7 n.s. n.s.
Pyruvate# 0.75F0.3 (n=10) 0.35x 0.93 0.75x 0.79F0.10 (n=3) 0.76F0.27# (n=12) 1.01F0.23 0.42 0.47
Pyruvate/CS§ 65F27# (n=10) 44x 56x 48x 95F42 (n=3) 76F23# (n=13) 125F29 0.70 1.15
Succinate/CS§ 67F17 (n=10) 38x 38x 77x 96F46 (n=3) 74F28# (n=13) 112F29 0.50 0.74
SRPR [%] 79F21#*(n=10) n.d. 95 46x 81F21 (n=3) 85F29# (n=13) 119F36 0.43 0.57
SRNO [%] 28F14# (n=16) 21x 15x 23x 43F9 (n=5) 32F14 (n=21) 43F19 0.30* 1.03
COX-negative fibers [%] 17F11z(n=14) 27m 48m 22m 16F7z (n=4) 16F10z (n=18) 0.18F0.17 0.69 0.42
Type I fibers [%] 46F7 (n=7) n.d. 43 53 47F4 (n=4) 46F6 (n=11) 43F6 n.s. n.s.
Heteroplasmy [%] 50F17 (n=16) 69 66 62 46F18 (n=5) 49F17 (n=21) 0.0 n.def. n.def.
Enzyme activities were detected as described in Materials and methods and given as meansFS.D. of specific (U/g noncollagen protein) activities or scaled by CS activity. Rates of respiration were measured under
state 3 conditions with 10 mM pyruvate/2 mM malate or 10 mM succinate/20 AM rotenone as substrates. Data as nmol O2/min/mg permeabilized fiber (#) or as pmol O2/min/U CS (§). SRPR, succinate-referenced
pyruvate respiration; SRNO, succinate-referenced NADH oxidation. COX-negative fibers were detected by COX/SDH-double staining as described in Materials and methods. Percentage of type I fibers was
determined in biopsies of m. biceps brachii by counting the dark fibers of SDH staining.
Data as means of n patientsFS.D. Number of controls was 46 except for type I fibers and COX-negative fibers where n was 15. Significant changes:z,# P<0.01;z*,#* P<0.05. Data of three index patients 1, 2
and 3 (see Table 1) with single deletions are presented. xm, outside the control range.
The last columns contain statistical results. Data of all patients with multiple plus single deletions were plotted versus heteroplasmy. m—correlation coefficient with P<0.01; or m*—P<0.05 (Pearson-test) for data.







































the maximum rate of respiration (state 3) was observed. After
inhibition of complex I with rotenone, the rate of respiration
decreased. Since succinate metabolism does not involve
complex I but complex II, it was possible to record the
succinate-dependent respiration. In the control muscle (Fig.
3A), pyruvate-dependent respiration was higher (138%) than
succinate-dependent respiration (100%). For all 47 controls,
this succinate-referenced pyruvate respiration (SRPR) was
118F31% (Table 2). Similar results were obtained if the state
3 respiration was measured in separate incubations with
single substrates. Under these conditions, pyruvate respira-
tion (1.01F0.23 nmol O2/min/mg s.w.; n=47) was 112% of
succinate respiration (0.90F0.28 nmol O2/min/mg s.w.;
n=47). The calculated SRPR (115F32; n=47) for measure-
ments in individual fibers was very similar to that obtained
for the sequential measurement in one fiber. State 4 respira-
tion was measured after inhibition of the AdN-translocator
by 1.8 mM actractyloside.
Fig. 3B shows the respirogram of a patient with a single
deletion at a heteroplasmy of 35% and a deletion size of 5
kb. Both pyruvate- and succinate-dependent state 3 respira-
tion rates were reduced in comparison to the controls.
Moreover, in this patient, the SRPR was also remarkably
reduced (58%), which is in line with the strongly reduced
activity of complex I+III (80%) in this patient. Atracty-
late-insensitive respiration was slightly increased in com-
parison to the controls. The respirogram (Fig. 3C) of a
second patient with 4 kb deletion (44% heteroplasmy)
shows nearly normal rates of state 3 respiration. However,
the CS-referenced state 3 respiration (83 pmol O2/min/U
Fig. 1. Specific CS activity versus heteroplasmy and deletion size in skeletal muscle of CPEO patients. Citrate synthase activity measured in muscle biopsies of
patients with single (o) and multiple (.) deletions was plotted versus the degree of heteroplasmy (A) and the deletion size (B). The control range was
calculated from 46 patients without muscle diseases as meansFS.D. The results of Pearson’s test were (A) r=0.58, P<0.01 (n=67, with controls); r=0.49,
P<0.05 (n=22, without controls). (B) n.s. (n=16, without controls).
Fig. 2. Activity of COX versus heteroplasmy of deletions and the deletion size. (A) COX activity was normalized by scaling of CS activity and plotted versus
heteroplasmy of mitochondrial defect in CPEO patients with single (o) and multiple (.) deletions. The correlation coefficients were r=0.75, P<0.01 (n=67,
with controls) and r=0.58, P<0.01 (n=22, without controls). (B) Normalized COX activity versus the size of deletion. There was no significant correlation.
Numbers indicate the data points of patients 1, 2 and 3.
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CS) was clearly reduced in this patient due to increased CS
activity (110 U/g NCP). Also, the SRPR (77%) was typi-
cally but modestly reduced compared to the controls, which
was accompanied by slightly reduced activity of complex
I+III, too. Similar respirograms were obtained from patients
with multiple deletions, too (not shown). The SRPR was
also decreased in these patients (Table 2).
In Fig. 4, state 3 respiratory rates of all investigated
patients for the substrate pyruvate/malate were plotted
versus heteroplasmy. The specific respiratory rates (scaled
by the fiber weight) are shown on the right. Obviously, there
was no correlation between respiration and the hetero-
plasmy. A complete change occurred after normalization
of respiratory rates on CS, whereby a clear and significant
linear correlation with heteroplasmy was detectable.
3.4. Changes on the morphological level
If COX activity inversely correlates with heteroplasmy of
deletions, then it should be expected that the number of
COX-negative fibers increases with the heteroplasmy of
deletions too. As shown in Fig. 5, there is a clear correlation
of COX-negative fibers with heteroplasmy (r=0.69,
P=0.0015). The proportion of COX-negative fibers was
16.6% (single) and 16.3% (multiple) in patients with dele-
tions (Table 2). We also detected a significant correlation
Fig. 3. Typical oxygraphic traces of mitochondrial respiration in saponin-skinned human muscle fibers of two CPEO patients with single deletions and of a
control patient. Investigation of mitochondrial function by a sequential multiple substrate-inhibitor titrations. Incubation of skinned fibers as described in
Materials and methods. The thick lines indicate the oxygen concentration in the oxygraph (left Y-axis). The thin lines represent the first derivative of these
signals directly indicating the respiratory rate (right Y-axis). Rates of respiration were measured in the presence of 10 mM pyruvate plus 2 mM malate.
Additions: D, 5 mM ADP; R, 20 AM rotenone (for inhibition of complex I); S, 10 mM succinate; A, 1.8 mM atractylate (for inhibition of the AdN-translocator).
(A) Normal respiratory pattern of a control patient without muscle disease. The pyruvate-dependent respiration is higher than the succinate-dependent
respiration (CS=63.0 U/g NCP, I+III/CS=12.2%). (B) Reduced rates of pyruvate and succinate respiration and of SRPR in a patient with single deletions.
Deletion size=5.5 kb; 34% heteroplasmy; I+III/CS=2.4%. (C) Reduced SRPR but normal rates of pyruvate and succinate respiration in a patient with single
deletions. Deletion size=4 kb, 44% heteroplasmy, CS 110 U/g NCP; I+III/CS=6.3%.
Fig. 4. Influence of different kinds of references to relation between maximum rate of pyruvate-dependent respiration (state 3) and heteroplasmy. Pyruvate-
dependent rates of respiration were measured under state 3 conditions in muscle biopsies of patients with single (o) and multiple (.) deletions in comparison
to controls as described in Fig. 3. Means of at least three different incubations scaled by CS (A) or by sample weight (B) were plotted versus the level of
heteroplasmy. Correlation coefficients: (A) r=0.62, P<0.01 (n=60, with control) and r=0.73, P<0.01 (n=13, without controls). (B) Not significant.
Numbers indicate the data points of patients 1, 2 and 3.
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between the number of ragged red fibers and heteroplasmy
(data not shown). The percentage of type I fibers was
detected by succinate dehydrogenase staining. Data
obtained from m. biceps brachii in patients (46F6%,
n=11) and controls (43F6%, n=12) are shown in Fig. 5B
and Table 2. There was no detectable correlation between
type I fibers and heteroplasmy and no change in the fiber
pattern was detectable in the patients in comparison to the
controls.
3.5. Comparison of changes of enzymatic and functional
level
To compare the extent of deletion-dependent changes on
enzymatic and functional level, we scaled both kinds of data
by the respective mean values of controls and plotted them
versus the level of heteroplasmy (Fig. 6). Due to this
scaling, the slopes of regression line indicating the extent
of heteroplasmy-dependent change are directly comparable.
These slopes and the correlation coefficients obtained by the
Pearson test are presented in Table 2. Slopes of regression
lines are similar for the complexes of the respiratory chain
(COX, III, II+III, and I+III) except for SDH. The change in
SDH activity was only half of the others. Interestingly, the
slopes of scaled rates of pyruvate and succinate respiration
were practically the same as the slopes of the respiratory
chain complexes.
3.6. Influence of the kind of deleted genes on biochemical
changes
Three patients were selected with different defined dele-
tions and nearly the same levels of heteroplasmy (Table 1).
As mentioned above, these deletions included the common
deletion (4.9 kb), the smallest (2.5 kb), and the largest (9 kb)
deletion found in our patients. Biochemical data of these
patients are shown in Table 2. In addition, in Figs. 1,2,4 and
5, the data points of these patients are marked by numbers.
As shown in Fig. 1 and Table 2 biopsies of the three
patients strongly vary in specific CS activity. Whereas CS
activity was normal in patient 1 (55 U/g NCP), elevated
activities were detected in patients 2 (109 U/g NCP) and 3
(131 U/g NCP), indicating large differences in mitochon-
drial content. The specific rates of respiration are different
(Table 2 and Fig. 4B) increasing with the numbers of
Fig. 5. Correlation of COX-negative fibers and Type I fibers with heteroplasmy in CPEO patients. Percentage of COX-negative fibers was measured by
sequential staining of COX and SDH in skeletal muscle of patients with single (o) and multiple (.) deletions. Percentage of type I fibers was determined only
in m. biceps brachii by succinate dehydrogenase staining. Correlation coefficients: (A) r=0.85, P<0.01 (n=30, with controls), r=0.69, P<0.01 (n=17,
without controls). (B) n.s. (n=24, without controls). Numbers indicate the data points of patients 1, 2 and 3.
Fig. 6. Comparison of changes on enzymatic and functional level in muscle
mitochondria of CPEO patients. Enzyme activities and respiratory rates
were scaled by the control values (100%) and plotted versus heteroplasmy.
First-order regression lines are shown. Further statistical data are given in
Table 2. (1) Citrate synthase (U/g NCP); (2) SDH/CS; (3) succinate
respiration (state 3/CS); (4) I+III/CS; (5) pyruvate respiration (state 3/CS);
(6) COX/CS; (7) II+III/CS; (8) III/CS.
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patients. After normalization, rates of respiration were
essentially the same (Fig. 4A). As shown in Fig. 2B, the
normalized COX-activities were also equal in the three
patients, despite the large differences in the affected genes.
In patient 2, besides the tRNAL, tRNAS, and tRNAH genes,
only the genes for ND5 and ND4 were deleted. The COX
activity, however, was decreased as in the two other patients
where COX subunits were also affected. A similar situation
was found for complex III (Table 2). The loss of COX
activity in patient 2 was also accompanied by the presence
of 22% COX-negative fibers.
4. Discussion
4.1. Mitochondrial function measured in skinned muscle
fibers
For investigation of mitochondrial function in human
muscle biopsies, we used the skinned fiber technique [27–
29,31] and high-resolution respirometry [30,31]. One limit-
ing disadvantage of the skinned fiber technique is the
uncertainty of the exact amount of mitochondria present
within the individual fibers under investigation, which may
be varied by, e.g. pathological proliferation [49] and phys-
ical training [50]. CS activity is commonly used for quanti-
fying the content of mitochondria due to its tight correlation
with morphometric data [51] and due to its resistance to
pathological changes.
In this paper, we demonstrated that in patients with single
deletions at a heteroplasmy of 50F17%, the amount of
mitochondria was nearly doubled. Therefore, even remark-
ably decreased enzyme activities can be compensated by
increased amounts of mitochondria. The diagnostic rele-
vance of this effect is that non-normalized functional and
enzymatic data obtained from muscle fibers and from
muscle homogenates become inconspicuous. The decreased
specific functional and enzymatic data are clearly detectable
only in some patients with low amounts of mitochondria. As
shown in Fig. 4, the diagnostic sensitivity is increased by
CS normalization. Our data therefore confirm the necessity
of normalization of functional data [21,22].
It may be speculated that increasing the amount of
mitochondria in diseased skeletal muscle could be a
strategy to minimize functional consequences of deletions.
The large variations of specific CS activity by the factor of
7, as detected in our patients, shows the possibility that the
normal density of mitochondria (3–6% of cell volume) can
be doubled without problems for cell functioning. How-
ever, in tissues with mitochondrial densities between 20%
and 30% (e.g. heart, brain), this may be not possible
without further disadvantages for the tissues. In this
respect, the skinned fibers with both kinds of references
are a model for understanding the consequences of mito-
chondrial density on genotype phenotype relations in
deleted mtDNA.
A second strategy for consideration of different mito-
chondrial density is the sequential measurement of pyru-
vate- and succinate-dependent state 3 respiration in the same
fiber. A decreased pyruvate respiration in one individual
fiber could be the result of decreased mitochondrial content
or the result of an impairment. The scaling of pyruvate
respiration by the succinate respiration can easily distin-
guish between these possibilities since the calculated ratio of
SRPR is independent of the content of mitochondria. In
normal muscle, the pyruvate respiration is, in our hands,
higher than the succinate respiration (112–118%). This was
found in normal incubations measured with single substrates
as in sequential incubations as well. Both kinds of measure-
ments were done in the additional presence of rotenone,
which is necessary to avoid inhibition of succinate dehy-
drogenase by oxaloactetate [52].
In patients with single deletions, SRPR was significantly
decreased by 34% (Table 2) and correlated with hetero-
plasmy of deletions. Therefore, it seems that CPEO is
associated with decreased SRPR in skeletal muscle. The
reason for decreased SRPR is most probably the pronounced
decrease in complex I activity in comparison to the lesser
decrease in the activity of complex II. This conclusion is
supported by our recent findings that diminished rates of
SRPR were also detectable in the heart and skeletal muscle
mitochondria of aged Fisher rats, which clearly correlated
with decreased activities of complex I and I+III and the
more or less unchanged activity of complex II [53].
A further approach to detecting pathological changes
with functional measurements is the estimation of flux
control coefficients by means of inhibitor titrations [54–
56]. This technique was successfully used in human [57]
and animals samples [34], but the method needs relatively
large amounts of material to allow sufficient replicates.
4.2. Functional investigation of AdN-translocator
It was proposed that inactive AdN-translocator due to
missense point mutations could be the reason for induced
multiple deletions of CPEO patients [10]. This mutation
caused a lethal loss of mitochondrial function in yeast cells
[10]. However, no mutations were found by sequencing the
whole coding region of AdN-translocator gene 1 in the three
patients with autosomal inherited multiple deletions. This
result is in line with the detection of functionally sufficient
AdN-translocation in mitochondria of patients with multiple
deletions (Table 2). Firstly, there was a clear stimulation of
respiration by ADP-addition from state 2 to state 3, indicat-
ing that ADP can be transported by AdN-translocator into
the matrix space. Secondly, there was an inhibition of state 3
respiration by actractyloside in the same manner in both
groups of patients. Moreover, we found that changes of
enzyme activities and of mitochondrial function in patients
with single and multiple deletions were quite similar (Table
2; (Figs. 1, 2 and 4, 5)). Therefore, it is concluded that at
least in our patients with multiple deletions, the AdN-
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translocator as well as other nuclear coded OXPHOS
enzymes were not affected and probably not the cause of
the autosomal inheritance of the disease.
4.3. Consequences of deletions on mitochondrial enzymes
Normalized activities of COX, complexes I, I+III, II+III
and III linearly decreased with increasing heteroplasmy in
biopsies of CPEO patients with both single and multiple
deletions. The best fit was observed for normalized COX,
which linearly decreased with heteroplasmy. These results
confirm previously reported data [13] but are contradictory
to others [63]. The slopes of the regression lines for all
measured complexes of the respiratory chain were close
together (between 1.07 and 0.83), indicating that all
changes follow the same mechanism. We detected also
decreased activities of complex II+III and SDH in our
CPEO patients. We did not expect these changes since
SDH is a nuclear coded mitochondrial enzyme. Interest-
ingly, the decrease in SDH activity was only half of that
for the other complexes of the respiratory chain. This
clearly points at another mechanism of impairment. It
was recently hypothesized that the Fe–S cluster-containing
components of the SDH are a privileged target for super-
oxides [58], which might be increasingly formed at
impaired respiratory chain similar to that shown in Frie-
dreich’s ataxia where frataxin is missing [59].
Interestingly, the decrease in complex II+III is more
pronounced than the decrease in SDH. Activity of complex
II+III mainly reflects activity of complex II [60,61], but (in
a lesser extent) also the activity of complex III [60,61],
which is affected like the other complexes. Therefore, the
decrease in activity of complex II+III could be higher than
for complex II alone.
4.4. Similar consequences of deletion caused impairment
on enzymatic and functional level
Interestingly, the size of deletion had obviously no influ-
ence on the CS activity (Fig. 1B), on the normalized COX
activity (Fig. 2B), and the rates of normalized respiration (not
shown). Therefore, it seems that very different deletions
produce the same phenotype on the level of mitochondrial
function where the impairment depends only on the hetero-
plasmy. These results confirm reports where variation of
deletion size between 1.8 to 8.8 kb did not correlate with
respiratory chain enzymes [62]. Stronger support for this
point of view came from the comparison of the selected
patients 1, 2, and 3. In these patients, deletions differed in size
and localization. Only subunits of complex I were affected at
the genome level in patient 2, but the activities of complex III
and COX were similarly affected as in patients 1 and 3.
Obviously, the loss of the three tRNA for leucine, serine, and
histidine caused the comparable disturbances in mitochond-
rially coded subunits of respiratory chain including those of
COX and complex III.
Deletions of mtDNA have at least two different con-
sequences at different levels of mitochondrial protein syn-
thesis. Missing structure genes cause dysfunction at the
level of transcription. The resulting impairment at the level
of mitochondrial function depends on the importance of the
deleted protein for the total function. Missing tRNAs,
however, cause dysfunction at the level of translation. This
translation defect necessarily affects all mitochondrial coded
structure proteins and should have a higher impact on the
impairment of mitochondria. Data show that, at least in our
patients, mitochondrial dysfunction and COX activity line-
arly correlate with heteroplasmy despite differences in the
pattern of affected structure genes. This very clearly points
at greater importance of defects at the level of translation
over those at the level of transcription. As shown earlier
[63], mitochondrial proliferation was able to normalize the
level of mRNA of deleted genes, but this would also further
increase transcripts of nondeleted genes [63]. This might be
comparable to the increased activity of CS found in affected
muscles of our and other studies [13,62].
As shown in Figs. 2 and 4, the changes of COX activity
and of the state 3 respiration were found to be dependent
to the same extent on the level of heteroplasmy. Moreover,
the slopes of the normalized activity versus heteroplasmy
plots (Table 2) were nearly the same for the respiratory
rates (e.g. 1.15 for pyruvate) as for the complexes of the
respiratory chain (e.g. 0.93 for COX). This is only
apparently not in agreement with the low flux control
coefficients of COX and other single complexes of respi-
ratory chain in human skeletal muscle. Mazat et al. [14]
showed that the single COX activity is more sensitive than
the rate of respiration to the inhibitory action of KCN. In
those experiments, COX of normal mitochondria was
specifically inhibited by KCN, and the other complexes
of the respiratory chain remained unaffected. In our present
measurements, however, COX is not separately decreased
but is additionally accompanied by parallel declines in
other respiratory chain complexes. Therefore, the changes
in COX activity are an indicator of simultaneous changes
in probably all enzymes with mtDNA coded proteins, and
it is not permissible to draw conclusions on the flux
control of a single affected complex. Together, these
enzymes have practically entire control of oxidative phos-
phorylation, which explains the parallel decrease in func-
tional and enzymatic data and the absence of thresholds in
this kind of disease.
In conclusion, we have shown that in skeletal muscle of
CPEO patients with deleted mtDNA, normalized mito-
chondrial function and normalized activity of respiratory
chain complexes linearly correlate with heteroplasmy.
Mitochondrial impairment did not correlate with the size
of deletion in mtDNA, which points at a large pathoge-
nicity of the deleted tRNAs. The missing threshold at the
level of mitochondrial function due to large-scale deletions
seems to be a characteristic of CPEO as a special form of
mitochondrial translation disease.
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